

**CHARACTERISATION OF *Plasmodium falciparum* PFMDR1 GENE
MUTATIONS IN MALARIA PATIENTS FROM SELECTED
HOSPITALS IN OTA, OGUN STATE, NIGERIA**

**ARIRIGUZOH, VICTORIA-GRACE ONYEKACHI
(22PCQ02456)**

B. Sc Microbiology, Mountain Top University, Ibafo, Ogun State

AUGUST, 2024

**CHARACTERISATION OF *Plasmodium falciparum* PFMDR1 GENE
MUTATIONS IN MALARIA PATIENTS FROM SELECTED
HOSPITALS IN OTA, OGUN STATE, NIGERIA**

BY

**ARIRIGUZO, VICTORIA-GRACE ONYEKACHI
(22PCQ02456)**

B. Sc Microbiology, Mountain Top University, Ibafo, Ogun State

**A DISSERTATION SUBMITTED TO THE SCHOOL OF
POSTGRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE AWARD OF MASTER OF SCIENCE (M.
Sc) DEGREE IN MICROBIOLOGY IN THE DEPARTMENT OF
BIOLOGICAL SCIENCES, COLLEGE OF SCIENCE AND
TECHNOLOGY, COVENANT UNIVERSITY, OTA, OGUN STATE,
NIGERIA**

AUGUST, 2024

ACCEPTANCE

This is to attest that this dissertation is accepted in partial fulfilment of the requirements for the award of the degree of Master of Science in Microbiology in the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Nigeria

Miss. Adefunke F. Oyinloye
(Secretary, School of Postgraduate Studies)

Signature and Date

Prof. Akan B. Williams
(Dean, School of Postgraduate Studies)

Signature and Date

DECLARATION

I, **ARIRIGUZOH, VICTORIA-GRACE ONYEKACHI (22PCQ02456)** declare that this research was carried out by me under the supervision of Professor Olayemi O. Akinnola of the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Nigeria. I attest that the dissertation has not been presented either wholly or partially for the award of any degree elsewhere. All sources of data and scholarly information used in this dissertation are duly acknowledged.

ARIRIGUZOH VICTORIA-GRACE ONYEKACHI

Signature and Date

CERTIFICATION

We certify that this dissertation titled “**CHARACTERISATION OF *Plasmodium falciparum* PFMDR1 GENE MUTATIONS IN MALARIA PATIENTS FROM SELECTED HOSPITALS IN OTA, OGUN STATE, NIGERIA**” is an original research work carried out by **ARIRIGUZO, VICTORIA-GRACE ONYEKACHI** in the Department of Biological Sciences, College of Science and Technology, Covenant University, Ota, Ogun State, Nigeria under the supervision of Professor Olayemi O. Akinnola. We have examined and found this work acceptable as part of the requirements for the award of Master of Science in Microbiology.

Professor Olayemi O. Akinnola
(Supervisor)

Signature and Date

Dr Isaac O. Ayanda
(Head of Department)

Signature and Date

Professor Segun I. Oyedeji
(External Examiner)

Signature and Date

Professor Akan B. Williams
(Dean, School of Postgraduate Studies)

Signature and Date

DEDICATION

For my dear mom, without whom my academic achievements would not have been possible. Your unwavering support, encouragement, and sacrifices have been the driving force behind my success. Thank you for always believing in me and pushing me to be my best self. This project is dedicated to you with all my love and gratitude.

ACKNOWLEDGEMENTS

I am deeply grateful to the Almighty God for granting me the opportunity and grace to complete this work. Without His divine favour, this accomplishment would not have been possible.

My heartfelt thanks go to my supervisor, Professor Olayemi Akinnola, for her invaluable guidance and constructive feedback, which helped shape this research. I also sincerely thank the Head of the Department of Biological Sciences, Dr. Isaac Ayanda, as well as the Department of Biological Sciences lecturers, particularly Dr. Margaret Oniha, Professor Conrad Omonhimmin, and the late Professor Grace Olasehinde, for their support and encouragement.

I am profoundly thankful to my sponsors, the Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), for financing this research. Special thanks to the esteemed Centre Director, Professor Emeka Iweala, for his leadership and unwavering support.

I would also like to acknowledge Mr. Olabode Onile-Ere for his invaluable contributions, especially in the area of Bioinformatics and statistical analysis. My thanks also go to Mr. Olabode Omotosho, Mr. Kilsa Borgbara, Miss Odunayo Balogun, and Miss Bolu Awosanya of Inqaba Biotech for their assistance during this research.

I owe a debt of gratitude to my beloved mother, Dr. Stella Aririguzoh, for her boundless love, support, and unwavering belief in me throughout my academic journey. Her sacrifices and encouragement have been a constant source of strength and motivation.

I also want to thank Professor Lanre Amodu for his mentorship and support. I want to appreciate the chaplain of my Alma Mater Mountain Top University, Pastor Adesina Olumide Faith for supporting me in prayers.

Lastly, I am deeply appreciative of my dear friends, Mameh Emmanuel Ojochegbe, Oyegbade Samuel Adeniyi, Balogun Daniel Oluwatobiloba, Ajao Ademolu Daniel, Adebowale Paul Oluwasegun, Oba Emmanuel Babatunde, Davies Priscilla Anu, Akwudike Ifeoma Esther, and Oyesile Oluwapelumi Sola, for their moral support and encouragement.

May God bless and reward each one of you abundantly.

Thank you all.

TABLE OF CONTENTS

CONTENT	PAGE
COVER PAGE	i
TITLE PAGE	ii
ACCEPTANCE	iii
DECLARATION	iv
CERTIFICATION	v
DEDICATION	vi
ACKNOWLEDGEMENTS	vii
LIST OF TABLES	xi
LIST OF FIGURES	xii
ABSTRACT	xiii
ABBREVIATIONS	xiv
CHAPTER ONE: INTRODUCTION	1
1.1. Background to the Study	1
1.2 Statement of the Research Problem	2
1.3 Research Questions	3
1.4. Aim and Objectives	3
1.4.1 Research Objectives	3
1.5. Justification for the Study	3
1.6 Scope of Study	3
CHAPTER TWO: LITERATURE REVIEW	5
2.1 Overview of Malaria	5
2.2 Malaria Epidemiology	5
2.2.1 Transmission Dynamics	8
2.3 Malaria Endemicity	9
2.4 Causative Agents of Malaria	9
2.5 Life Cycle of <i>Plasmodium</i>	12
2.6 Clinical Manifestations of Malaria	13
2.7 Diagnosis of Malaria	15
2.7.1 Clinical Diagnosis	15
2.7.2 Laboratory Diagnostic Methods	15
2.7.2.1 Microscopy	15
2.7.2.2 Rapid diagnostic tests	16
2.7.2.3 Polymerase Chain Reaction	16
2.7.3 Challenges in Diagnosis	17
2.7.4 Emerging Diagnostic Technologies	18
2.7.4.1 Loop-Mediated Isothermal Amplification (LAMP)	18
2.7.4.2 Digital Microscopy	18
2.7.4.3 Next-Generation Sequencing (NGS)	18
2.7.4.4 Biosensors and Microfluidic Devices	18
2.7.4.5 Artificial Intelligence (AI) and Machine Learning	19
2.8 Treatment of Malaria	19
2.8.1 Combination Therapies	19
2.8.2 Non-ACT Combination Therapies	20

2.8.3	Chloroquine	20
2.8.4	Intravenous (IV) Artesunate	20
2.8.5	Intravenous Quinine	21
2.8.6	Supportive Care	21
2.8.7	Alternative and Adjunctive Therapies	21
2.8.8	Treatment Guidelines and Protocols	22
2.9	Antimalarial Drugs and Their Modes of Action	22
2.9.1	Chloroquine	22
2.9.2	Artemisinin-Based Combination Therapies (ACTs)	23
2.9.3	Quinine and Quinidine	24
2.9.4	Primaquine	24
2.9.5	Atovaquone-Proguanil	24
2.10	Mechanisms of Drug Action	24
2.11	Factors Influencing Resistance	27
2.11.1	Genetic Mutations	28
2.11.2	Gene Amplification and Copy Number Variations	28
2.11.3	Drug Pressure and Misuse	29
2.12	Mechanisms of Malaria Resistance	29
2.12.1	Target Site Mutations	30
2.12.2	Drug Transporter Mutations	31
2.12.3	Adaptive Changes in Parasites	31
2.13	Timeline of Antimalaria Resistance	32
2.14	Detecting Resistance	33
2.14.1	Phenotypic Assays	33
2.14.2	<i>In Vitro</i> Drug Sensitivity Assays	33
2.14.3	<i>Ex Vivo</i> Drug Sensitivity Assays	34
2.14.4	<i>In Vivo</i> Efficacy Studies	34
2.14.5	Genotypic Methods	35
2.14.6	Polymerase Chain Reaction (PCR)	35
2.14.7	Sequencing and Genotyping	35
2.14.8	High-Throughput Genotyping Assays	35
2.14.9	Surveillance Systems	36
2.14.10	Global Surveillance Initiatives	36
2.14.11	Technological Advances in Detection	37
2.15	<i>Pfmdr1</i>	38
2.15.1	Role in Drug Resistance	38
2.15.2	Genetic Variability	39
2.15.3	Challenges in Treatment of Malaria	41
2.16	Point Mutations in <i>Pfmdr1</i>	41
2.17	Effect of <i>Pfmdr1</i> on Other Antimalarial Drugs	43
2.18	Impact of Resistance on Treatment	46
2.19	Malaria Drug Resistance Control Strategies	46
2.20	Preventing Resistance	47
2.21	Research Gaps	51
CHAPTER THREE: MATERIALS AND METHODS		52
3.1	Materials	52
3.1.1	Equipment	52

3.1.2	Materials	52
3.2	Methods	52
3.2.1	Ethical Approval	52
3.2.2	Informed consents	52
3.2.3	Study Population	52
3.2.4	Study Site	53
3.2.5	Sampling Size	54
3.2.6	Sample Collection	55
3.2.7	Microscopy	55
3.2.8	DNA Extraction	56
3.2.8	DNA Quantification	56
3.2.9	PCR amplification for Confirmation of Malaria	57
3.2.10	Gel electrophoresis	58
3.2.11	PCR Amplification for <i>Pfmdr1</i> Detection	58
3.2.12	Post-PCR Purification	58
3.2.13	Sequencing	59
3.2.14	Statistical Analysis	59
CHAPTER FOUR: RESULTS		60
4.1	Prevalence of Malaria In Study Location	60
4.2	Prevalence of <i>Pfmdr1</i> in The Study	65
4.3	<i>Pfmdr1</i> Mutations Identified Within the Isolates	68
CHAPTER FIVE: DISCUSSION		73
CHAPTER SIX: CONCLUSION AND RECOMMENDATION		77
6.1	Summary	77
6.2	Conclusion	77
6.3	Contributions to Knowledge	78
6.4	Recommendations	79
REFERENCES		80
APPENDICES		95
APPENDIX I: Ethical Approval		95
APPENDIX II: Nanodrop Spectrophotometer Results		96
APPENDIX III: Agarose Gel Images		100
APPENDIX IV: PCR amplification		103
APPENDIX V: Post-PCR Purification		104

LIST OF TABLES

TABLES	TITLES	PAGES
Table 2. 1	A timeline of the evolution of resistance to anti-malarial drugs	32
Table 3.1	Primer pairs used to amplify and sequence Pfmdr1	57
Table 3:2	PCR Working Solution	58
Table 4.1	The Prevalence of <i>Plasmodium falciparum</i> infection Among Clinical Isolates	60
Table 4:2	Age Groups and Malaria Infection	61
Table 4.3	Prevalence of <i>Plasmodium falciparum</i> infection based on both age group and gender	62
Table 4:4	The Prevalence of <i>Pfmdr1</i> infection Among Clinical Isolates	65
Table 4:5	Comparison of <i>Pfmdr1</i> infection between Medical Centre and General Hospital	67
Table 4:6:	Pfmdr1 SNPs Mutations present in samples	68
Table 4:7:	<i>Pfmdr1</i> Wildtype and Mutations present in samples	69
Table 4:8	Prevalence of <i>Pfmdr1 mutations</i> based on both age group and gender	71
Table 4.9	Comparison of Mutation Prevalence Between Medical Centre and General Hospital	72

LIST OF FIGURES

FIGURES	TITLES	PAGES
Figure 2.1:	Malaria incidences and Fatalities in the WHO African Region	6
Figure 2.2:	Malaria deaths by country in 2022	7
Figure 2.3:	Haemosporidian parasite schematic phylogenetic tree	11
Figure 2.4:	Life Cycle of <i>P. falciparum</i>	13
Figure 5:	Antimalarial mechanism of action	26
Figure 2.6:	A diagram showing the global frequencies of mutations in the pfmdr1, pfert and pfexo genes	33
Figure 3.1:	Map of Nigeria with Ogun State Highlighted	54
Figure 3.1:	Agarose Gel Images to Confirm Malaria	63
Figure 3.2:	Relationship Between Parasitaemia and Age	64

ABSTRACT

Malaria continues to be a significant global health problem, especially in tropical and subtropical areas. The 2023 World Malaria Report by the World Health Organization reveals that there were 249 million cases of malaria and 608,000 fatalities in 2022. A significant obstacle in malaria control is the rise and spread of resistance to antimalarial drugs, which endangers the efficacy of current therapies and undermines worldwide endeavours to eradicate the illness. The efficacy of routinely used antimalarial medicines, such as artemisinin-based combination treatments (ACTs), is increasingly endangered by the formation and spread of multi-drug resistance (MDR). The *Plasmodium falciparum* multidrug resistance 1 gene (*Pfmdr1*) is frequently linked to multi-drug resistance. This study was conducted to detect the presence and prevalence of the *Pfmdr1* gene in *Plasmodium falciparum* isolated from malaria-positive blood samples to understand its role in anti-malaria drug resistance within Ota, Ogun State, Nigeria. Ethical approval was obtained from the Covenant Health Research Ethics Committee, Ogun state, Nigeria, before the commencement of the study. Three hundred and fifty-six blood samples were obtained from outpatients attending Covenant University Medical Centre and the General Hospital, Ado-Odo Ota, Ogun State. Microscopy was used to identify *P. falciparum* in all samples. The prevalence of malaria was recorded at 66%, with the age group of children ≤ 10 having the highest prevalence at 80%. DNA extraction was performed to isolate *P. falciparum* from 50 malaria-positive blood samples. Nested PCR was performed to identify and amplify the *Pfmdr1* gene and determine its mutations. The prevalence of the *Pfmdr1* was recorded at 66% among samples amplified using two-step Nested PCR. Sanger Sequencing was carried out on 10 samples to provide a detailed genetic characterization of the *Pfmdr1* gene and three mutations of the *Pfmdr1* gene the F74L, Y184F and S164S were identified.

KEYWORDS: *Malaria, Multidrug resistance, Gene Mutations, Prevalence*